Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis Models: Efficacy, Safety, and Mechanistic Innovations

Cannabinoids are emerging as promising treatments for inflammatory diseases such as ulcerative colitis. Specifically, cannabinoid 2 (CB2) receptors, which are upregulated during inflammation, have been distinctively linked to anti-inflammatory and analgesic effects. HU308, a synthetic cannabinoid de...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cells (Basel, Switzerland) Ročník 13; číslo 23; s. 2013
Hlavní autoři:	Thapa, Dinesh, Patil, Mohan, Warne, Leon N, Carlessi, Rodrigo, Falasca, Marco
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland MDPI AG 01.12.2024 MDPI
Témata:	Acute Disease Ammonia Analgesics Animal models Animals Anti-inflammatory drugs Cannabidiol cannabidiol (CBD) Cannabidiol - pharmacology Cannabidiol - therapeutic use cannabinoid 2 receptor Cannabinoid CB2 receptors Cannabinoids Cannabinoids - pharmacology Cannabinoids - therapeutic use Chronic Disease Chronic illnesses Colitis - chemically induced Colitis - drug therapy Colitis, Ulcerative - chemically induced Colitis, Ulcerative - drug therapy Colon Colon - drug effects Colon - metabolism Colon - pathology Cytokines - metabolism Design Dextran Dextran Sulfate Disease Models, Animal Drinking water Drug dosages Experiments Female Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide 1 - metabolism Glucose HU308 Inflammation Inflammatory bowel disease inflammatory bowel disease (IBD) Inflammatory bowel diseases Innovations Laboratory animals Male Mice Mice, Inbred C57BL Pain Receptor, Cannabinoid, CB2 - metabolism Side effects Sodium sulfate Toxicity Tumor necrosis factor-TNF Ulcerative colitis United States Illinois Missouri St Louis Missouri United States > US HU308 cannabidiol (CBD) cannabinoid 2 receptor ulcerative colitis inflammatory bowel disease (IBD) inflammation
ISSN:	2073-4409, 2073-4409
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Cannabinoids are emerging as promising treatments for inflammatory diseases such as ulcerative colitis. Specifically, cannabinoid 2 (CB2) receptors, which are upregulated during inflammation, have been distinctively linked to anti-inflammatory and analgesic effects. HU308, a synthetic cannabinoid developed to activate CB2 receptors selectively, aims to minimize unwanted off-target side effects. This study evaluated the effectiveness of both cannabidiol (CBD) and HU308 in mouse models of dextran sodium sulphate (DSS)-induced colitis, which mimic the acute and chronic phases of ulcerative colitis. Mice were treated with DSS in drinking water (four percent for the acute model and one to two percent for the chronic model) to induce colitis, as indicated by increased disease activity index (DAI) scores and inflammatory markers. Treatment with 60 mg/kg of CBD, but not lower doses, significantly reduced colitis symptoms, such as inflammation, cytokine levels, and MPO activity, while also normalizing glucagon-like peptide-1 (GLP-1) levels. HU308 showed comparable efficacy to high-dose CBD (60 mg/kg) but at a much lower dose (2.5 mg/kg), without observable toxicity. HU308 effectively normalized DAI scores, colon inflammation, ammonia levels, and GLP-1 expression in both colitis models. These results suggest that both CBD and HU308 are promising treatments for ulcerative colitis. However, HU308 demonstrates enhanced therapeutic potential by achieving similar outcomes at a fraction of the dose required for CBD, reducing the risk of off-target side effects. The ability of HU308 to modulate GLP-1, a biomarker of gut endocrine function, further underscores its promise as a novel treatment option.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work.
ISSN:	2073-4409 2073-4409
DOI:	10.3390/cells13232013